

# Tiapride hydrochloride

Cat. No.: HY-B1196 CAS No.: 51012-33-0 Molecular Formula:  $C_{15}H_{25}CIN_{2}O_{4}S$ 

Molecular Weight: 365

Target: **Dopamine Receptor** 

Pathway: GPCR/G Protein; Neuronal Signaling

4°C, sealed storage, away from moisture and light Storage:

\* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture

and light)

**Product** Data Sheet

## **SOLVENT & SOLUBILITY**

In Vitro

 $H_2O : \ge 200 \text{ mg/mL} (547.95 \text{ mM})$ 

DMSO: 31.25 mg/mL (85.62 mM; Need ultrasonic) \* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.7397 mL	13.6986 mL	27.3973 mL
	5 mM	0.5479 mL	2.7397 mL	5.4795 mL
	10 mM	0.2740 mL	1.3699 mL	2.7397 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: PBS Solubility: 100 mg/mL (273.97 mM); Clear solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 0.62 mg/mL (1.70 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 0.62 mg/mL (1.70 mM); Clear solution
- 4. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 0.62 mg/mL (1.70 mM); Clear solution

### **BIOLOGICAL ACTIVITY**

Description

Tiapride hydrochloride is a selective and orally active D<sub>2</sub> and D<sub>3</sub> dopamine receptors antagonist with IC<sub>50</sub> values of 110-320 nM and 180 nM, respectively. Tiapride hydrochloride shows anti-dyskinetic activity and anxiolytic activity. Tiapride hydrochloride is a neuroleptic agent<sup>[1][2]</sup>.

IC <sub>50</sub> & Target	D <sub>2</sub> Receptor 110-320 nM (IC <sub>50</sub> )	D <sub>3</sub> Receptor 180 nM (IC <sub>50</sub> )
	110-320 HW (IC50)	100 HM (IC50)

#### **REFERENCES**

[1]. Scatton B, et al. The preclinical pharmacologic profile of tiapride. Eur Psychiatry. 2001 Jan;16 Suppl 1:29s-34s.

[2]. Peters DH, et al. Tiapride. A review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome. Drugs. 1994 Jun;47(6):1010-32.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA